Global Blood Therapeutics (GBT) Declines; Doctors on Cowen Panel Said Skeptical on GBT440 Mechanism - Bloomberg
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Global Blood Therapeutics (NASDAQ: GBT) Declines; Doctors on Cowen Panel Said Skeptical on GBT440 Mechanism - Bloomberg
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla's (TSLA) Price Target Cut to Street Low of $155 at Cowen
- Global Blood Therapeutics (GBT) Commences GBT440 Phase 2a in IPF
- Global Blood Therapeutics Announces GBT440 Granted Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease
Create E-mail Alert Related CategoriesTrader Talk
Related EntitiesCowen & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!